Qualitative assessment of healthy volunteer experience receiving subcutaneous infusions of high-dose benzathine penicillin G (SCIP) provides insights into design of late phase clinical studies
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0285037 ↗Kurz gefasst
Klinische Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von Stephanie L Enkel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, Australia. Hauptthemen laut MEDLINE: Penicillin G Benzathine, Rheumatic Heart Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cure Kids, Strep A PhD Scholarship and a Scholarship for International Research Fees, Post Graduate Research Scholarship & Althestan Saw Bequest Fund.
Abstract (Originalsprache)
Introduction
Secondary prophylaxis to prevent rheumatic heart disease (RHD) progression, in the form of four-weekly intramuscular benzathine benzylpenicillin G (BPG) injections, has remained unchanged since 1955. Qualitative investigations into patient preference have highlighted the need for long-acting penicillins to be delivered less frequently, ideally with reduced pain. We describe the experience of healthy volunteers participating in a phase-I safety, tolerability and pharmacokinetic trial of s ub c utaneous i nfusions of high-dose benzathine p enicillin G (BPG)–the SCIP study (Australian New Zealand Clinical Trials Registry ACTRN12622000916741).
Methods
Participants (n = 24) received between 6.9 mL to 20.7 mL (3–9 times the standard dose) of BPG as a single infusion into the abdominal subcutaneous tissues via a spring-driven syringe pump over approximately 20 minutes. Semi-structured interviews at four time points were recorded, transcribed verbatim and thematically analysed. Tolerability and specific descriptors of the experience were explored, alongside thoughts on how the intervention could be improved for future trials in children and young adults receiving monthly BPG intramuscular injections for RHD.
Results
Participants tolerated the infusion well and were able describe their experiences throughout. Most reported minimal pain, substantiated via quantitative pain scores. Abdominal bruising at the infusion site did not concern participants nor impair normal activities. Insight into how SCIP could be improved for children included the use of topical analgesia, distractions via television or personal devices, a drawn-out infusion time with reduced delivery speed, and alternative infusion sites. Trust in the trial team was high.
Conclusion
Qualitative research is an important adjunct for early-phase clinical trials, particularly when adherence to the planned intervention is a key driver of success. These results will inform later-phase SCIP trials in people living with RHD and other indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, Australia.
- Medical School, University of Western Australia, Crawley, Western Australia, Australia.
- Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
- Clinical Pharmacology and Toxicology Unit, PathWest, Perth, Western Australia, Australia.
- Department of Public Health, University of Otago, Wellington, New Zealand.
- Te Kupenga Hauora Maori, University of Auckland, Auckland, New Zealand.
ORCID-Profile: Stephanie L Enkel, Sam Salman
Förderung
- Cure Kids
- Strep A PhD Scholarship and a Scholarship for International Research Fees
- Post Graduate Research Scholarship & Althestan Saw Bequest Fund
- National Health and Medical Research Council
- Research Training Program
- Wesfarmers Centre of Vaccines and Infectious Diseases Top Up scholarship
Zitieren
APA
Enkel, S. L., Kado, J., Hla, T. K., Salman, S., Bennett, J., Anderson, A., Carapetis, J. R., & Manning, L. (2023). Qualitative assessment of healthy volunteer experience receiving subcutaneous infusions of high-dose benzathine penicillin G (SCIP) provides insights into design of late phase clinical studies. PLOS ONE. https://doi.org/10.1371/journal.pone.0285037
Vancouver
Enkel SL, Kado J, Hla TK, Salman S, Bennett J, Anderson A, et al. Qualitative assessment of healthy volunteer experience receiving subcutaneous infusions of high-dose benzathine penicillin G (SCIP) provides insights into design of late phase clinical studies. PLOS ONE. 2023. doi:10.1371/journal.pone.0285037
BibTeX
@article{Enkel2023,
author = {Enkel, Stephanie L and Kado, Joseph and Hla, Thel K and Salman, Sam and Bennett, Julie and Anderson, Anneka and Carapetis, Jonathan R and Manning, Laurens},
title = {Qualitative assessment of healthy volunteer experience receiving subcutaneous infusions of high-dose benzathine penicillin G (SCIP) provides insights into design of late phase clinical studies},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0285037}
}
EUVIMED